This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Galectin Therapeutics To Present At Jefferies 2014 Global Healthcare Conference

NORCROSS, Ga., May 29, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company will present at the Jefferies 2014 Global Healthcare Conference, to be held June 2-5, 2014, in New York, NY. Dr. Harold H. Shlevin, Chief Operating Officer and Corporate Secretary of Galectin Therapeutics, will provide an overview of the Company's business and recent and upcoming milestones during his live presentation.

The Jefferies Global Healthcare Conference features an extensive range of public and private healthcare companies across the biopharmaceuticals, life sciences, healthcare services, healthcare information technology and medical technology sectors. Leading executives, institutional investors, private equity investors and venture capital firms will address near- and long-term investment opportunities and discuss the driving forces in the healthcare industry.

WHAT: Galectin Therapeutics presentation at Jefferies 2014 Global Healthcare Conference

WHO: Presentation by Dr. Harold Shlevin, Chief Operating Officer, Galectin Therapeutics

WHEN: Monday, June 2, 2014, 11 a.m. Eastern Daylight Time

Dr. Shlevin's presentation will be webcast live at http://wsw.com/webcast/jeff82/galt/. The archived webcast will be available for 90 days following the presentation.

For more information on the Jefferies 2014 Global Healthcare Conference, please visit http://www.jefferies.com/OurFirm/Conferences/325/148

About Galectin Therapeutics

Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com .

CONTACT: Galectin Therapeutics Inc.
         Dr. Harold H. Shlevin (678)-615-3213
         Chief Operating Officer
         shlevin@galectintherapeutics.com

Galectin Therapeutics, Inc. Logo

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,097.62 +62.69 0.35%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs